Tag: iShares U.S. Pharmaceuticals ETF
-
Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials
There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of its obesity portfolio.
-
Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising
Novo asked the court to permanently stop Lilly from running the “deceptive” ads and require the drugmaker to issue corrective advertising.
-
J&J falls despite a beat-and-raise quarter. Why we’re raising our price target anyways
Johnson & Johnson’s quarter was imperfect, but enough is going right to validate our ownership of the stock.
-
Impressive growth of Eli Lilly’s obesity business is coming from all over the world
Eli Lilly’s international GLP-1 business is booming, giving investors another reason to stick with the stock.
-
Pharma stocks are showing strength. Charts predict this name could break out next
Pharmaceutical stocks have recently separated themselves from the broader market, and the group has become a source of leadership within healthcare.
Latest News
Stay Connected
Categories
BBC News CNA CNBC CNN International Deutsche Welle (DW) Euronews France 24 General Global & European Specialized & Regional
Tags
amp Artificial intelligence Asia Breaking News: Markets Breaking News: Politics Breaking News: Technology Business business news china cup Donald J. Trump Donald Trump economy European Union fast football France germany Heatwave Investment strategy iran Iran war markets news People per politics return russia said Singapore spain Sport Stock markets technology trump ukraine United Kingdom United States US-Israel attack on Iran 2026 video War in Ukraine World world cup World Cup 2026
About the Author
AF themes
Easy WordPress Websites Builder: Versatile Demos for Blogs, News, eCommerce and More – One-Click Import, No Coding! 1000+ Ready-made Templates for Stunning Newspaper, Magazine, Blog, and Publishing Websites.
Search the Archives
Access over the years of investigative journalism and breaking reports
You May Have Missed
